<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00680680</url>
  </required_header>
  <id_info>
    <org_study_id>AUR</org_study_id>
    <nct_id>NCT00680680</nct_id>
  </id_info>
  <brief_title>Treatment of Refractory Urinary Retention Secondary to Benign Prostatic Hyperplasia (BPH) With Dual Five Alpha Reductase Inhibition Combined With an Alpha Blocker</brief_title>
  <acronym>AUR</acronym>
  <official_title>Phase 4 Study of Dual Five Alpha Reductase Inhibition Combined With Alpha Blockade in Men With Refractory Urinary Retention Secondary to BPH</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Franklin D. Gaylis, MD Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Franklin D. Gaylis, MD Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine whether the addition of a dual Five Alpha Reductase Inhitor (Dutasteride) will
      alleviate urinary retention secondary to BPH in who have failed a voiding trial without a
      catheter. Following treatment with an Alpha Blocker alone.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Urinary Retention</condition>
  <condition>Benign Prostatic Hyperplasia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dutasteride</intervention_name>
    <description>Patients will continue on their alpha blocker in addition to Dutasteride 0.5mg daily for a maximum of 3 months</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males betewen the ages of 50 and 90 years of age.Written informed consent.

          2. Men with acute urinary retention attributed to bladder outlet obstruction caused by
             BPH, who have failed atleast 1 week trial of alpha blocker treatment.

          3. PSA level equal to or greater than 1.5ng/ml and equal to or less than 15 ng/ml.

        Exclusion Criteria:

          1. Urinary retention attributed to a neurogenic or myogenic bladder dysfunction.

          2. Use of psychotrophic medications.

          3. Use of antichollinergic medications.

          4. Prostate cancer.

          5. Allery to five alpha reductase inhibitors.

          6. Prior prostate surgery.

          7. Urethral stricture.

          8. Bladder calculi.

          9. Invasive bladder cancer.

         10. Inability to understand or agree with the requirements of the study.

         11. Any investigational drug received within 30 days prior of study entry.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Franklin D Gaylis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director/Sponsor</affiliation>
  </overall_official>
  <verification_date>May 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2008</study_first_submitted>
  <study_first_submitted_qc>May 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2008</study_first_posted>
  <last_update_submitted>May 19, 2008</last_update_submitted>
  <last_update_submitted_qc>May 19, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2008</last_update_posted>
  <responsible_party>
    <name_title>Franklin D. Gaylis, M.D.</name_title>
    <organization>MEDRESEARCH</organization>
  </responsible_party>
  <keyword>Urinary retention secondary to benign prostatic hyperplasia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Urinary Retention</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dutasteride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

